Journal of Clinical Oncology 10(11): 1748-1753, 1992.
Einzig AI, Wiernik PH, Sasloff J, et al.
Based on the results of our Phase I study that demonstrated the antitumor activity of taxol in a previously treated patient with ovarian cancer, a Phase II study was conducted to evaluate the efficacy of taxol in patients with metastatic ovarian cancer and to evaluate further the toxicity of taxol in this group of patients.
Patients and Methods:
Thirty-four patients with metastatic ovarian cancer received taxol (180 to 250 mg/m2) as a 24-hour continuous infusion. A premedication regimen was used to reduce the likelihood of an acute hypersensitivity reaction.
Six of 30 assessable patients demonstrated complete responses (one patient) or partial responses (five patients; 20%; 95% confidence interval [CI], 6% to 34%; range, 2 to 30 months). Additionally, one patient had a less than partial objective response (2 months), and two patients had stable disease for 6 and 15 months. Those responders had a median survival of 27 months, and the nonresponders had a median survival of 6 months (P = .0001). Myelosuppression was the most significant toxicity. Other adverse effects included alopecia and peripheral neuropathy.
Taxol has significant activity in ovarian cancer and should be studied in combination with other active agents earlier in this disease.
Rheinische Friedrich- Wilhelms- Universität Bonn